JP2015512387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512387A5 JP2015512387A5 JP2015501721A JP2015501721A JP2015512387A5 JP 2015512387 A5 JP2015512387 A5 JP 2015512387A5 JP 2015501721 A JP2015501721 A JP 2015501721A JP 2015501721 A JP2015501721 A JP 2015501721A JP 2015512387 A5 JP2015512387 A5 JP 2015512387A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- gdf11
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 230000032683 aging Effects 0.000 claims 9
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 8
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 4
- 208000006029 Cardiomegaly Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010002906 aortic stenosis Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 claims 2
- 210000005003 heart tissue Anatomy 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000002027 skeletal muscle Anatomy 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612550P | 2012-03-19 | 2012-03-19 | |
| US61/612,550 | 2012-03-19 | ||
| US201261649962P | 2012-05-22 | 2012-05-22 | |
| US61/649,962 | 2012-05-22 | ||
| PCT/US2013/030140 WO2013142114A1 (en) | 2012-03-19 | 2013-03-11 | Growth differentiation factor (gdf) for treatment of diastolic heart failure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512387A JP2015512387A (ja) | 2015-04-27 |
| JP2015512387A5 true JP2015512387A5 (enExample) | 2016-04-07 |
| JP6124986B2 JP6124986B2 (ja) | 2017-05-10 |
Family
ID=49223184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501721A Active JP6124986B2 (ja) | 2012-03-19 | 2013-03-11 | 拡張期心不全を処置するための増殖分化因子（ｇｄｆ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9434779B2 (enExample) |
| EP (1) | EP2828289B1 (enExample) |
| JP (1) | JP6124986B2 (enExample) |
| CA (1) | CA2901394A1 (enExample) |
| ES (1) | ES2779698T3 (enExample) |
| WO (1) | WO2013142114A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| JP5931874B2 (ja) | 2010-08-13 | 2016-06-08 | ソマロジック・インコーポレーテッド | 膵癌バイオマーカーおよびその使用 |
| SG10201607331WA (en) * | 2011-09-30 | 2016-11-29 | Somalogic Inc | Cardiovascular risk event prediction and uses thereof |
| JP2016518357A (ja) * | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
| EP3881859B1 (en) * | 2013-06-11 | 2024-03-06 | President and Fellows of Harvard College | Compositions for increasing neurogenesis and angiogenesis |
| WO2015073396A1 (en) * | 2013-11-12 | 2015-05-21 | The Brigham And Women's Hospital, Inc. | Growth differentiation factor (gdf) for treatment of diastolic heart failure |
| EP3142680A4 (en) * | 2014-05-16 | 2018-05-23 | Intermune, Inc. | Lpa-associated protein and rna expression |
| WO2016049662A1 (en) * | 2014-09-23 | 2016-03-31 | President And Fellows Of Harvard College | Methods and compositions for treating age-related disorders |
| AU2015353767B2 (en) | 2014-11-24 | 2021-09-09 | Somalogic Operating Co., Inc. | Nucleic acid compounds for binding growth differentiation factor 11 |
| WO2017115789A1 (ja) | 2015-12-28 | 2017-07-06 | 国立研究開発法人理化学研究所 | 加齢による生理機能の低下を回復または改善する組成物 |
| CA3010799A1 (en) | 2016-01-06 | 2017-07-13 | President And Fellows Of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
| WO2019144053A1 (en) * | 2018-01-19 | 2019-07-25 | President And Fellows Of Harward College | Gdf11 variants and uses thereof |
| US20200222459A1 (en) * | 2019-01-16 | 2020-07-16 | Melvin Barnes | System, Method and Compositions for Treating Age-Related Illnesses and Conditions |
| JP2022001603A (ja) * | 2021-10-14 | 2022-01-06 | 功 加治佐 | 自分由来ｉＰＳ若い血液応用ＧＤＦ１１分子コーティング若返り経口不老不死薬９ |
| CN114989310B (zh) * | 2022-06-20 | 2024-11-19 | 深圳先进技术研究院 | 一种嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及应用 |
| CN115212299A (zh) * | 2022-06-21 | 2022-10-21 | 深圳先进技术研究院 | Car-t和car-m联用在制备抗肿瘤药物中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4612302A (en) | 1983-11-14 | 1986-09-16 | Brigham And Women's Hospital | Clinical use of somatostatin analogues |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| PT698094E (pt) * | 1993-05-12 | 2004-05-31 | Inst Genetics Llc | Composicoes de bmp-11 |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| EP0985149A1 (en) | 1997-05-30 | 2000-03-15 | Creative Biomolecules, Inc. | Methods for evaluating tissue morphogenesis and activity |
| US20030170213A1 (en) * | 1998-01-23 | 2003-09-11 | Marc F. Charette | Methods and compositions for enhancing cognitive function using morphogenic proteins |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| US20060078532A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| WO2004073633A2 (en) * | 2003-02-14 | 2004-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating the development of stem cells |
| NZ529860A (en) | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
| EP1858546A4 (en) | 2005-03-04 | 2009-03-04 | Biorexis Pharmaceutical Corp | MODIFIED TRANSFERRINFUSION PROTEINS |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2007142818A2 (en) | 2006-05-17 | 2007-12-13 | Stryker Corporation | Use of a soluble morphogenic protein complex for treating cartilage defects |
| TWI573802B (zh) * | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| EP3141905B1 (en) | 2008-03-27 | 2019-03-06 | Promega Corporation | Protein labeling with cyanobenzothiazole conjugates |
-
2013
- 2013-03-11 JP JP2015501721A patent/JP6124986B2/ja active Active
- 2013-03-11 ES ES13764561T patent/ES2779698T3/es active Active
- 2013-03-11 US US14/385,578 patent/US9434779B2/en active Active
- 2013-03-11 EP EP13764561.0A patent/EP2828289B1/en active Active
- 2013-03-11 CA CA2901394A patent/CA2901394A1/en active Pending
- 2013-03-11 WO PCT/US2013/030140 patent/WO2013142114A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512387A5 (enExample) | ||
| EP4234017A3 (en) | 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) | |
| Naveen et al. | Case Report: Variant origin of an arterial trunk from axillary artery continuing as profunda brachii artery-a unique arterial variation in the axilla and its clinical implications | |
| DK1728507T3 (da) | Anvendelse af vitamin K for at omvende forkalkning af blodkar | |
| JP2015521611A5 (enExample) | ||
| Cork et al. | A case series of biventricular circulatory support using two ventricular assist devices: a novel operative approach | |
| Giusca et al. | Portopulmonary hypertension: from diagnosis to treatment | |
| JP2017530954A5 (enExample) | ||
| Lebedyantseva et al. | Structural abnormalities in periodontal tissues in chronic apical periodontitis | |
| Radwan et al. | Acute aortic dissection imitating ST elevation myocardial infarction with accompanying pulmonary embolism | |
| Zavalloni et al. | Anomalous origin of the left coronary artery from the pulmonary artery in an adult pregnant patient: surgical and percutaneous myocardial revascularization | |
| Gokalp et al. | Clinically asymptomatic myocardial bridging in a child with familial subaortic stenosis | |
| Hieda et al. | Acute effects of adaptive servo-ventilation on hemodynamics in advanced chronic heart failure patients | |
| Franklin | The pathobiology of isolated systolic hypertension | |
| Mejia et al. | Jumping and Pumping: Balancing Physical Activity and Anticoagulation in Ventricular Assist Devices | |
| Aimo | Surgical Anatomy of Coronary Arteries: Morphogenesis, Normal and Pathological Anatomy | |
| Wagenaar | Osteoporosis: a cardiovascular risk factor equivalent to type 2 diabetes: drug trends in cardiology | |
| Fritz et al. | Multivessel myocardial bridging in a patient with spiral hypertrophic cardiomyopathy | |
| Ali | Hypertensive vascular disease | |
| Ahmed et al. | Late stent fracture-A potential role of left ventricular dilatation | |
| Kraiem et al. | P4718 Follow up in heart failure center versus routine practice: which positive impact we can have? | |
| Murali et al. | INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES | |
| Hayashi et al. | P3293 One year result of the underfilling strategy in transcatheter aortic valve implantation with balloon expandable valve | |
| Otsuka et al. | Gender differences between left and right ventricular diastolic function in normal subjects | |
| Wenzelburger et al. | Torsional dyssynchrony on exercise is linked to left ventricular hypertrophy in patients with heart failure and preserved ejection fraction |